Royal Bank of Canada
MAZE

Royal Bank of Canada’s Maze Therapeutics MAZE Stock Holding History

Royal Bank of Canada’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61K Buy
2,029
+1,383
+214% +$61K ﹤0.01% 5393
2025
Q4 		$27K Buy
646
+363
+128% +$12.5K ﹤0.01% 5884
2025
Q3 		$7K Sell
283
-803
-74% -$13.6K ﹤0.01% 6618
2025
Q2 		$13K Buy
1,086
+953
+717% +$9.91K ﹤0.01% 6421
2025
Q1 		$1K Buy
+133
New +$1.6K ﹤0.01% 6748

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's MAZE Position: Q1 2026 in Review

Royal Bank of Canada increased its Maze Therapeutics (MAZE) stake by 214% in Q1 2026, buying an estimated $61K and bringing the position to 2,029 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #5393.

Royal Bank of Canada first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Royal Bank of Canada held 2,029 shares of Maze Therapeutics worth $61K as of Q1 2026.
  • Royal Bank of Canada bought 1,383 Maze Therapeutics shares in Q1 2026, an estimated $61K.
  • Maze Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5393 holding.
  • Royal Bank of Canada first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.